Acute Myeloid Leukaemia Aml clinical trials

Explore recruiting acute myeloid leukaemia aml clinical trials.

Recruiting acute myeloid leukaemia aml studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Acute Myeloid Leukaemia Aml trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

HOVON 171 AML: A single arm phase II trial to assess cobicistat boosted venetoclax in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (AML) who are not considered candidates for intensive treatment regimens

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Single-centre Phase I/II study with dose escalation of tocilizumab in combination with venetoclax and azacitidine chemotherapy in patients with Acute Myeloid Leukaemia (AML): TOCIVENA

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Multicentre, open-label, phase 1/2 study of LB-208, selective antagonist of the serotonin 5-hydroxytryptamine receptor 1B (HTR1B), in adults with relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A phase I/II multi-centre study to assess the tolerability and efficacy of the addition of hydroxyurea to standard ara-C and daunorubicin-based therapy for adults (age ≥ 18 years of age) with newly diagnosed acute myeloid leukaemia (AML)

Sweden

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies.

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced haematological malignancies

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Acute Myeloid Leukaemia Aml trials by city

Acute Myeloid Leukaemia Aml in Toronto Acute Myeloid Leukaemia Aml in Vancouver Acute Myeloid Leukaemia Aml in Montreal Acute Myeloid Leukaemia Aml in Calgary Acute Myeloid Leukaemia Aml in Edmonton Acute Myeloid Leukaemia Aml in Ottawa Acute Myeloid Leukaemia Aml in Winnipeg Acute Myeloid Leukaemia Aml in Quebec City Acute Myeloid Leukaemia Aml in Hamilton Acute Myeloid Leukaemia Aml in Kitchener Acute Myeloid Leukaemia Aml in London Acute Myeloid Leukaemia Aml in Halifax Acute Myeloid Leukaemia Aml in New York Acute Myeloid Leukaemia Aml in Los Angeles Acute Myeloid Leukaemia Aml in Chicago Acute Myeloid Leukaemia Aml in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease